hs-CRP: what your result means.

High-sensitivity C-reactive protein (hs-CRP) measures low-grade chronic inflammation, the kind that quietly damages arteries for years without symptoms. It is one of the most validated inflammation markers in cardiovascular medicine.

Why hs-CRP matters

Chronic vascular inflammation destabilises arterial plaque. Large prospective studies underpin the ACC/AHA risk bands: below 1.0 mg/L signals low cardiovascular risk, while values above 3.0 mg/L roughly double the risk of a cardiac event compared with low levels, independent of cholesterol.

Associated risks when out of range: Chronic inflammation. Cardiometabolic risk. Plaque instability.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets hs-CRP, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• Women's Health Study (Ridker et al. NEJM 2000): hs-CRP was the strongest single inflammatory predictor of cardiovascular events in ~28,000 healthy women, stronger than LDL cholesterol, and identifying at-risk women whose lipids looked normal.
• Emerging Risk Factors Collaboration (The Lancet 2010): individual data from 54 long-term cohorts (~160,000 people) confirmed a continuous association between hs-CRP and coronary heart disease, stroke and vascular mortality.
• JUPITER trial (Ridker et al. NEJM 2008): in ~17,800 people with elevated hs-CRP but normal LDL, rosuvastatin cut major vascular events by 44%, proof that inflammation identifies risk that cholesterol testing alone misses.
• CANTOS trial (Ridker et al. NEJM 2017): targeting inflammation directly (canakinumab) reduced cardiovascular events by 15% with no lipid change at all, the landmark proof that vascular inflammation is causal, not a bystander.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets hs-CRP against published clinical authority standards, never arbitrary "optimal" ranges. Measured in mg/L:

Clinical interpretation

• Must be measured away from acute infection, trauma, or surgery, these can spike hs-CRP >100x baseline.
• hs-CRP <1.0 mg/L is low cardiovascular risk; 1.0–3.0 is intermediate risk; >3.0 is high cardiovascular risk.
• AHA/ACC: if hs-CRP >10 mg/L, testing should be repeated when the patient is clinically stable to distinguish chronic vascular inflammation from an acute-phase response. Do not interpret a single >10 reading as chronic cardiovascular risk.
• Statin therapy, exercise, weight loss, and omega-3 supplementation all reduce hs-CRP.

What improves it: the evidence-based levers

• Weight reduction
• Sleep optimisation
• Exercise
• Omega-3 optimisation
• Investigate acute illness if >10

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How hs-CRP testing works at HodieLabs

hs-CRP is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843.
2. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132–140.
3. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359:2195–2207.
4. Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377:1119–1131.
5. Arnett DK, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140:e596–e646.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.